TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited reported a significant increase in its half-year profits, with a net profit after tax of A$15.0 million, marking an 88% rise compared to the previous year. This growth was driven by increased royalty revenue from Acadia, which rose to A$28.3 million. Despite the profit surge, the company did not declare any dividends and completed a share buy-back program worth $39.6 million, reflecting its strategic financial management.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on developing therapies for neurodevelopmental disorders. The company generates revenue primarily through royalty agreements, notably with Acadia Pharmaceuticals.
Average Trading Volume: 496,304
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$2.23B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.